Premium
Effect of Obesogenic Medications on Weight‐Loss Outcomes in a Behavioral Weight‐Management Program
Author(s) -
Desalermos Athanasios,
Russell Baylee,
Leggett Cecilia,
Parnell Amelia,
Ober Kathleen,
Hagerich Kelley,
Gerlan Cindy,
Ganji Gelareh,
Lee Euyhyun,
Proudfoot James A.,
Grunvald Eduardo,
Gupta Samir,
Ho Samuel B.,
Zarrinpar Amir
Publication year - 2019
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.22444
Subject(s) - weight loss , medicine , weight management , odds ratio , medical prescription , odds , obesity , physical therapy , logistic regression , pharmacology
Objective This study aimed to evaluate a possible association between the use of obesogenic medications and inadequate weight loss in a behavioral weight‐management program. Methods This is a case‐control, single‐center study of 666 adult patients within a Veterans Health Administration health system who participated in the MOVE! behavioral weight‐loss program. The cohort was divided into responders ( n = 150), patients who achieved ≥ 5% total weight loss by the end of the MOVE! program, and nonresponders ( n = 516), those who achieved < 5% total weight loss. We reviewed each patient’s medical records for exposure to obesogenic medication during the time of treatment. Results Approximately 62% ( n = 411) of patients entering MOVE! had a prescription for obesogenic medications. Obesogenic medication use was associated with worse weight‐loss outcomes, and participants were 37% less likely to achieve a clinically meaningful (≥ 5% total weight loss) outcome at the end of the MOVE! program (odds ratio, 0.633; 95% CI: 0.427‐0.937; adjusted P = 0.022). Patients who received three or more medications ( n = 72) had the greatest difficulty achieving 5% weight loss compared with the control group (odds ratio, 0.265; 95% CI: 0.108‐0.646; adjusted P = 0.003). Conclusions The use of provider‐prescribed obesogenic medications was associated with worse weight‐loss outcomes in a behavioral weight‐loss program. Closer scrutiny of patient medications is necessary to help improve outcomes of weight‐loss treatments.